Clinical Development DNA Small Molecule 
Drug Target Review
JULY 18, 2023
AI is being used to find the targets themselves, design the drugs to manipulate that biology, and thirdly, AI is being used to support validation of those targets and drugs as part of pre-clinical development. Cavlan explains that “they are brilliant at developing and bringing new drugs to market.”
The Premier Consulting Blog
JULY 9, 2023
During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. What sets this guidance apart from ICH Q3A and ICH Q3B is that it applies to all stages of clinical development, not just to approval.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Nvidia Developer: Drug Discovery
MARCH 21, 2023
New supercomputing-scale large language models (LLMs) that understand biology and chemistry text are helping scientists understand proteins, small molecules, DNA, and biomedical text. These state-of-the-art AI models help generate de novo proteins and molecules and predict the 3D structures of proteins.
The Pharma Data
JUNE 28, 2021
Broadens company’s oncology platform of Targeted Alpha Therapies / Acquisition includes actinium-225 labeled differentiated PSMA small molecule for the treatment of prostate cancer. It has been demonstrated to inflict difficult to repair damage to tumor cells by inducing DNA double strand breaks.
The Pharma Data
MAY 15, 2023
The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation. Both programs have the potential to address multiple indications, offering broad development opportunities alone and in combination with Gilead’s portfolio.
LifeSciVC
MARCH 1, 2023
They also highlighted why targeting the CD28 pathway overcomes some of these challenges and why CBL-B modulation, downstream of CD28 and other signaling receptors with clinical validation, may be more advantageous.
The Pharma Data
OCTOBER 14, 2020
Assistant Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons, is designed to generate DNA aptamer-based anti-idiotypes to selected monoclonal antibodies identified in Dr. Ilya Trakht’s study. The study led by Dr. Sergei Rudchenko, Ph.D., 1 Noyce RS, et al. 2018) PLoS One. 13(1):e0188453.
Expert insights. Personalized for you.
98 
Let's personalize your content